Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cilostazol in Diabetic PAD (DORIC)
NCT02983214Phase 4Completed
- Sponsor
- University of Ioannina
- Start
- Nov 2016
- Primary completion
- Oct 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of cilostazol in peripheral artery disease (PAD) and type 2 diabetes mellitus (T2DM) (2 arms), sponsored by University of Ioannina. Primary endpoints: Composite of acute ischemic stroke/transient ischemic attack (TIA), myocardial infarction (MI), or death from vascular causes at 12 months and Bleeding events as defined by BARC criteria at 12 months. Started Nov 2016; status: completed.
02
Drugs
cilostazol
03
Conditions
peripheral artery disease (PAD)type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT02983214.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02983214.